Method Profile
Measure how patient-matched cancer-associated fibroblasts modify organoid chemotherapy response.
Investigate stromal contributions to chemotherapy resistance in lung adenocarcinoma.
Treatment-naïve lung adenocarcinoma organoids and matched cancer-associated fibroblasts.
Organoid drug-response comparisons with fibroblasts and CLGN perturbation.
Matched models
Tumor organoids and fibroblasts from the same patient-derived tumor material.
Mechanistic comparison
PLAU-positive fibroblast state, CXCL5 signaling and CLGN perturbation.
Connect the coculture drug-response change with the candidate fibroblast-to-tumor signal.
Paired tumor–stroma model comparison and CLGN perturbation.
Patient-derived lung adenocarcinoma organoids and patient-matched cancer-associated fibroblasts.
Organoid drug response with or without fibroblast coculture and after CLGN removal.
Fibroblast coculture reduced sensitivity, while CLGN removal restored drug response.
Patient-matched lung adenocarcinoma organoids and fibroblasts connected a stromal cell state with drug resistance. The study implicated a PLAU–CXCL5–CLGN signaling relationship.
